Award of task order #2 (manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with microsatellite instability) under contract 75N91019D00025 current POP: 9/19/19-7/18/20.…
Ended Awarded Last action
- Contract number
- 75N91019F00130
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,873,113
Award facts
- Opportunity
-
- N01CN8700618 Solicitation number
- Contract value 93% obligated
-
- $3,873,112.97 Current, with exercised options
- $4,174,177.97 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $66,248 | |
| Other Administrative Action | $0 | |
| Change Order | $93,199 | |
| Supplemental Agreement for work within scope | $2,243,667 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,469,999 |
Show all 17
About this award
This is a task order award under Contract 75N91019D00025 with the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute. The task order is for the manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with microsatellite instability. The prime contractor is Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization specializing in gene therapies, vaccines, oncolytics, and immunotherapies. The contract has a current period of performance from September 19, 2019 to July 18, 2020, with potential extension through May 31, 2024. The award has a potential value of $4,174,177.97 and is a cost-plus-fixed-fee contract. There is no set-aside designation indicated for this task order.
Description
Award of task order #2 (manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with microsatellite instability) under contract 75N91019D00025 current POP: 9/19/19-7/18/20. If options exercised, POP may be extended through 3
Quick answers
Who was awarded contract 75N91019F00130?
75N91019F00130 was awarded to Advanced Bioscience Laboratories, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2019.
How much is contract 75N91019F00130 worth?
The government has obligated $3,873,113 on 75N91019F00130. Its potential value, with all options, is $4,174,178.
Is contract 75N91019F00130 an order under another contract?
Yes. 75N91019F00130 is a delivery order under 75N91019D00025, an indefinite delivery contract, on PREVENT Cancer Preclinical Drug Development Program.
Was contract 75N91019F00130 competed?
The extent of competition for 75N91019F00130 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award